Pfizer's Covid-19 vaccine candidate offers some protection after the first dose, with nearly full protection after the second dose, according to documents released Tuesday by the Food and Drug Administration (12/8/20)
The information was made public before a meeting Thursday of the Vaccines and Related Biological Products Advisory Committee, or VRBPAC — an advisory group to the FDA that will vote on whether to advise the agency to grant emergency use authorization of the vaccine in the U.S.
1
